Chinese maker of endoscopy accessories — biopsy forceps, stents and snares — used with gastrointestinal endoscopes.
Chinese maker of endoscopy accessories — biopsy forceps, stents and snares — used with gastrointestinal endoscopes.
Its accessories are single-use, so revenue repeats with every procedure instead of resting on one-off equipment sales. A large part of sales goes overseas, mostly through local distributors and large device makers that resell the products.
In one line: A Chinese endoscopy-accessories supplier akin to a Boston Scientific Endoscopy niche.
Moat: narrow (regulatory licence, distribution). Broad global distribution network and device approvals across many markets.
Headquarters: Nanjing, Jiangsu, China · Founded: 1999 · Employees: 2,433
Size Micro-Tech (Nanjing) (688029.SS) is a China Health Care company (Medical Specialties) with a market value of $2.33B, the 1027th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥81.90 on 18 Nov 2026.
Performance Over six months the shares fell 0.5%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 6.3% over the last twelve months (peer median +7.5%); the operating margin is 18.5% (peer median 10.7%).
Valuation It trades at 28.1× forward earnings against a peer median of 24.2× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.5 points above its cost of capital (7.9% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.32B | CN¥3.17B | CN¥2.74B | CN¥2.39B | CN¥1.97B |
| Revenue growth | — | +16% | +14% | +22% | — |
| Gross profit | CN¥2.14B | CN¥1.92B | CN¥1.77B | CN¥1.48B | CN¥1.14B |
| EBITDA | n/a | CN¥741M | CN¥702M | CN¥531M | CN¥338M |
| Net income | CN¥477M | CN¥570M | CN¥553M | CN¥486M | CN¥331M |
| Free cash flow | CN¥535M | CN¥468M | CN¥400M | CN¥360M | CN¥84.7M |
| Capital expenditure | CN¥178M | CN¥255M | CN¥270M | CN¥256M | CN¥213M |
| Total debt | CN¥322M | CN¥251M | CN¥89.0M | CN¥45.1M | CN¥11.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Micro-Tech (Nanjing) 688029.SS | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Olympus 7733.T | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% |
| CONMED CNMD | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688029.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.6% | -1.6% | 10th highest of 21 |
| 6-month return | -0.5% | +1.1% | 9th lowest of 20 |
| Distance from 52-week high | -8.9% | -24.0% | 7th highest of 21 |
| Revenue growth (TTM) | +6.3% | +7.5% | 10th lowest of 20 |
| Operating margin | 18.5% | 10.7% | 5th highest of 20 |
| Forward P/E | 28.1× | 24.2× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 11.9% | 9.2% | 6th most demanding of 13 |
| Growth delivered (Del g) | +19.2% | +10.3% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | -7.3 pp | -2.5 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | +8.5 pp | -0.6 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |